Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.
Chong
A S
AS
Department of General Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60660.
Gebel
H
H
Finnegan
A
A
Petraitis
E E
EE
Jiang
X L
XL
Sankary
H N
HN
Foster
P
P
Williams
J W
JW
D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology*; D000077339:Leflunomide; D008213:Lymphocyte Activation / Q000187:drug effects; D011090:Polyenes / Q000494:pharmacology; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000528:radiation effects; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D011090:Polyenes; D014316:Tritium; D016572:Cyclosporine; D000077339:Leflunomide; D013936:Thymidine; D020123:Sirolimus